Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.) Issues Voluntary Nationwide Recall of Cetirizine Hydrochloride Tablets USP 5 mg Due to Potential Cross Contamination with Ranitidine
FOR IMMEDIATE RELEASE – July 18th, 2026 – Panoli, Gujarat, Unique Pharmaceutical Laboratories (A Div...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- FDA MedWatch
- Region
- USA
- Scope
- Regulatory
- Published
- July 20, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
FOR IMMEDIATE RELEASE – July 18th, 2026 – Panoli, Gujarat, Unique Pharmaceutical Laboratories (A Div...
Source route
Continue on fda.gov
Leave the platform to read the original full article on the publisher site.
Source: FDA MedWatch
Scope: Regulatory
Related coverage
More related coverage
Influenza vaccines marketed in the UK
Influenza vaccines marketed in the UK for 2026 to 2027, including ovalbumin content.
National mycobacterium reference service - South: user handbook
How to label, package and submit specimens to the laboratory for diagnostic testing.
Immunisation
Information for immunisation practitioners and other health professionals.
Bacteriology reference department user manual
A guide to UKHSA's bacteriology reference department (BRD), its units and the tests and services it...